Intuitive Surgical (ISRG) and Natera (NTRA) represent distinct segments within the healthcare sector, making their comparison relevant for investors seeking exposure to medical technology and precision diagnostics. ISRG specializes in robotic surgical systems, while NTRA develops molecular testing platforms focused on oncology and other areas. Traders and portfolio managers evaluating growth-oriented healthcare names may find this side-by-side analysis useful for assessing differences in business models, recent momentum, and risk profiles. The comparison draws on observable market data and company developments to highlight relative positioning without favoring either security.
Intuitive Surgical develops and markets the da Vinci surgical system for minimally invasive procedures across multiple specialties. The company generates revenue through system sales, instruments, and services, supported by a large installed base. In recent market activity, shares have traded in a range reflecting broader healthcare sector dynamics and specific procedure growth observations. Quarterly results showed revenue increases year-over-year alongside earnings that exceeded consensus estimates, yet investor focus shifted toward U.S. procedure trends and competitive developments. A peer-reviewed study published in recent weeks demonstrated improved patient outcomes associated with da Vinci procedures compared with alternative approaches across multiple conditions, providing potential support for adoption. Analyst ratings remain generally positive with a moderate buy consensus, though individual adjustments have occurred amid valuation considerations relative to historical levels.
Natera provides cell-free DNA testing services, with Signatera positioned as a key offering for minimal residual disease (MRD) monitoring in oncology. Revenue stems primarily from testing volumes in oncology, women’s health, and organ health applications. Recent market activity featured strong share price gains following presentation of large-scale clinical data at a major lung cancer conference, highlighting prognostic value in resected non-small cell lung cancer cases. Second-quarter results reflected substantial year-over-year revenue growth, prompting an upward revision to full-year guidance. The company continues to expand indications and partnerships while reporting ongoing net losses tied to research investments. Market capitalization and trading multiples reflect expectations around testing adoption rates and reimbursement progress in precision medicine.
Tickeron’s Trending AI Robots page curates a selection of high-performing automated trading strategies from hundreds of AI trading bots that operate across thousands of tickers. Only those demonstrating suitability for prevailing market conditions through consistent backtested metrics and adaptive parameters receive placement in this focused section. Available bots span diverse trading styles, timeframes, risk parameters, and performance statistics, allowing users to review detailed historical results and ticker-specific applicability. The platform emphasizes transparency in strategy logic and outcomes to support informed evaluation by active traders.
ISRG and NTRA operate in adjacent but non-overlapping healthcare niches, creating clear trade-offs. ISRG’s capital equipment model delivers recurring high-margin revenue from procedures with established regulatory clearances and global reach, whereas NTRA’s service-based approach scales with test volumes and benefits from rapid expansion into new oncology indications. Recent momentum favors NTRA on clinical data catalysts, while ISRG shows steadier long-term volume trends tempered by near-term growth moderation signals. Risk factors include ISRG’s exposure to hospital capital budgets and competition in robotics, contrasted with NTRA’s dependence on payer coverage and ongoing cash burn. Sector exposure places both in healthcare but differentiates equipment durability from diagnostic innovation cycles, influencing sentiment based on macroeconomic and regulatory environments.
Based on observable factors including trend consistency, recent clinical catalysts, and relative positioning within their respective subsectors, Tickeron’s AI models currently assign a higher probabilistic edge to NTRA for short-term momentum alignment, though ISRG demonstrates greater stability in earnings quality and market leadership. Outcomes remain contingent on execution of growth initiatives and broader market conditions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ISRG moved above its 50-day moving average on September 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 21 of 29 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 56 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for ISRG just turned positive on September 14, 2026. Looking at past instances where ISRG's MACD turned positive, the stock continued to rise in 26 of 44 cases over the following month. The odds of a continued upward trend are 59%.
The 10-day moving average for ISRG crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 58%.
Following a +2.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 211 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 183 of 264 cases where ISRG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
The 10-day RSI Indicator for ISRG moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 11 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 30%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.065) is normal, around the industry mean (5.011). P/E Ratio (47.568) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock better than average.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
NTRA saw its Momentum Indicator move below the 0 level on October 08, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned negative. In 81 of the 100 cases, the stock moved further down in the following days. The odds of a decline are at 81%.
The 10-day RSI Indicator for NTRA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 24 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 37 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
NTRA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 55 cases where NTRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +4.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 241 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 243 of 286 cases where NTRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.573) is normal, around the industry mean (72.578). P/E Ratio (0.000) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ISRG | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 81 | 11 | |
SMR RATING 1..100 | 51 | 94 | |
PRICE GROWTH RATING 1..100 | 42 | 35 | |
P/E GROWTH RATING 1..100 | 66 | 100 | |
SEASONALITY SCORE 1..100 | 90 | 16 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (54) in the Biotechnology industry is in the same range as ISRG (76) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to ISRG’s over the last 12 months.
NTRA's Profit vs Risk Rating (11) in the Biotechnology industry is significantly better than the same rating for ISRG (81) in the Medical Specialties industry. This means that NTRA’s stock grew significantly faster than ISRG’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is somewhat better than the same rating for NTRA (94) in the Biotechnology industry. This means that ISRG’s stock grew somewhat faster than NTRA’s over the last 12 months.
NTRA's Price Growth Rating (35) in the Biotechnology industry is in the same range as ISRG (42) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's P/E Growth Rating (66) in the Medical Specialties industry is somewhat better than the same rating for NTRA (100) in the Biotechnology industry. This means that ISRG’s stock grew somewhat faster than NTRA’s over the last 12 months.
| ISRG | NTRA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 30% | 1 day ago 63% |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 81% |
| MACD ODDS (%) | 1 day ago 59% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 65% | 1 day ago 83% |
| Advances ODDS (%) | 3 days ago 66% | 10 days ago 79% |
| Declines ODDS (%) | 13 days ago 61% | 1 day ago 76% |
| BollingerBands ODDS (%) | 1 day ago 48% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 69% | 1 day ago 85% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ISRG’s FA Score shows that 0 FA rating(s) are green while NTRA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ISRG’s TA Score shows that 6 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
ISRG (@Pharmaceuticals: Other) experienced а +4.27% price change this week, while NTRA (@Medical Specialties) price change was -1.25% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.23%. For the same industry, the average monthly price growth was -3.14%, and the average quarterly price growth was +7.32%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.57%. For the same industry, the average monthly price growth was +1.42%, and the average quarterly price growth was +38.10%.
ISRG is expected to report earnings on Oct 20, 2026.
NTRA is expected to report earnings on Nov 11, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-3.57% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | -1.30% | ||
| BSX - ISRG | 73% Closely correlated | -1.21% | ||
| SYK - ISRG | 64% Loosely correlated | -0.02% | ||
| NTRA - ISRG | 54% Loosely correlated | -0.53% | ||
| GKOS - ISRG | 51% Loosely correlated | -1.50% | ||
| PODD - ISRG | 49% Loosely correlated | -1.20% | ||
More | ||||
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ADPT. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | -0.53% | ||
| ADPT - NTRA | 55% Loosely correlated | -1.13% | ||
| NEO - NTRA | 54% Loosely correlated | +2.84% | ||
| ISRG - NTRA | 53% Loosely correlated | -1.30% | ||
| GH - NTRA | 52% Loosely correlated | -0.43% | ||
| TMO - NTRA | 48% Loosely correlated | +0.12% | ||
More | ||||